1      0

AM21-03: Challenges in Apheresis Cellular Collections during the COVID-19 Pandemic

‐ Oct 17, 2021 11:15am

Expiration Date: Dec 31, 2023

Credits: None available.

The field of cellular therapy has become increasingly complicated in all aspects, including technical, patient, environment, and regulatory. For example, the logistics of apheresis collection as well as the utilization of fresh stem cell product have changed significantly during the current COVID-19 pandemic. In this session, different logistical solutions that apheresis collection facilities have used during the pandemic will be discussed. New regulatory requirements introduced during the COVID-19 pandemic will be reviewed (e.g new FDA guidance) and how these can be implemented into routine operations will be discussed.

To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.

Learning Objectives:

  • Summarize different logistical modifications apheresis collection facilities adapted during the COVID-19 pandemic
  • Discuss different logistical modifications transplant centers have adapted during the COVID-19 pandemic
  • Review updated regulatory cellular therapy requirements during the COVID-19 pandemic and their effect on collection of cells for further manufacturing




  • Monika Paroder, MD, PhD:
    Nothing to Disclose
  • Huy Pham, MD, MPH:
    Consultant: Sanofi; Honoraria: Argenx; Royalty: Elsevier
  • Joseph Schwartz, MD, MPH:
    Consultant: Gamida Cell; Plass-Free, Argen X

All relevant financial relationships have been mitigated. By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.

Credits Available

AM21-03: Challenges in Apheresis Cellular Collections during the COVID-19 Pandemic Evaluation